Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

被引：0
|
作者：
T. Shiroiwa
T. Fukuda
K. Shimozuma
M. Mouri
Y. Hagiwara
H. Doihara
H. Akabane
M. Kashiwaba
T. Watanabe
Y. Ohashi
H. Mukai
机构：
[1] National Institute of Public Health,Department of Health and Welfare Services
[2] Ritsumeikan University,Department of Biomedical Sciences, College of Life Sciences
[3] Kanagawa Academy of Science and Technology (KAST),Department of Biostatistics, School of Public Health
[4] The University of Tokyo,Breast and Endocrine Surgery Department
[5] Okayama University Hospital,Department of Surgery
[6] Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital,Department of Surgery
[7] Iwate Medical University,Department of Breast Surgery
[8] Sendai Medical Center,Department of Integrated Science and Engineering
[9] Chuo University,Division of Breast and Medical Oncology
[10] National Cancer Center Hospital East,undefined
来源：
Quality of Life Research | 2017年 / 26卷
关键词：
Breast cancer; EQ-5D; Health-related quality of life; Randomized controlled trial; S-1; Taxane;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 453
页数：8
相关论文
共 47 条
  • [21] Comparison of EQ-5D Scores among Anthracycline-Containing Regimens followed by Taxane and Taxane-Only Regimens for Node-Positive Breast Cancer Patients after Surgery: The N-SAS BC 02 Trial
    Shiroiwa, Takeru
    Fukuda, Takashi
    Shimozuma, Kojiro
    Kuranami, Masaru
    Suemasu, Kimito
    Ohashi, Yasuo
    Watanabe, Toru
    VALUE IN HEALTH, 2011, 14 (05) : 746 - 751
  • [22] Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
    Kwakman, J. J.
    Van Werkhoven, E.
    Simkens, L. H.
    van Rooijen, J. M.
    van de Wouw, A.
    Ten Tije, A. J.
    Creemers, G-J.
    Hendriks, M. P.
    Los, M.
    van Alphen, R.
    Polee, M. B.
    Muller, E. W.
    Van der Velden, A.
    Van Voorthuizen, T.
    Koopman, M.
    Mol, L.
    Punt, C. J. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Orloff, M.
    Watkins, C.
    Carvajal, R. D.
    Shoushtari, A. N.
    Sacco, J. J.
    Schlaak, M.
    Gama, J.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S678 - S678
  • [24] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    Kang, Y.
    Lee, J.
    Min, Y.
    Lee, K.
    Zang, D.
    Ryoo, B.
    Kim, J.
    Park, S.
    Kang, W.
    Shin, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII25 - VII25
  • [25] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    Kang, Y.
    Lee, J.
    Min, Y.
    Lee, K.
    Zang, D.
    Ryoo, B.
    Kim, J.
    Park, S.
    Kang, W.
    Shin, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results
    Kim, Mi-Jung
    Kong, Sun-Young
    Nam, Byung-Ho
    Kim, Sohee
    Park, Young-Iee
    Park, Sook Ryun
    PHARMACOGENETICS AND GENOMICS, 2018, 28 (01): : 23 - 30
  • [27] A randomized phase III multicenter trial of doxorubicin and paclitaxel (AT) versus fluorouracil-doxorubicin-cyclophosphamide (FAC) as first-line therapy metastatic breast cancer (MBC): long-term efficacy and external review of results.
    Jassem, J
    Pluzanska, A
    Pienkouski, T
    Gershanovitch, MA
    Uziely, B
    Jelic, SS
    Biganzoli, L
    Gwyther, SJ
    Aloe, A
    Astier, L
    Munier, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S198 - S198
  • [28] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Yoshito Komatsu
    Chikashi Ishioka
    Ken Shimada
    Yasuhide Yamada
    Makio Gamoh
    Atsushi Sato
    Tatsuro Yamaguchi
    Satoshi Yuki
    Satoshi Morita
    Shin Takahashi
    Rei Goto
    Minoru Kurihara
    BMC Cancer, 15
  • [29] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Komatsu, Yoshito
    Ishioka, Chikashi
    Shimada, Ken
    Yamada, Yasuhide
    Gamoh, Makio
    Sato, Atsushi
    Yamaguchi, Tatsuro
    Yuki, Satoshi
    Morita, Satoshi
    Takahashi, Shin
    Goto, Rei
    Kurihara, Minoru
    BMC CANCER, 2015, 15
  • [30] A randomized phase ll study of S-1 versus capecitabine as first-line chemotherapy in the elderly metastatic gastric cancer patients with/without poor performance status: clinical and pharmacogenetic results.
    Park, Sook Ryun
    Kong, Sun-Young
    Kim, Mi-Jung
    Kim, Min Kyeong
    Nam, Byung-Ho
    Choi, Mihee
    Park, Young-lee
    CANCER RESEARCH, 2013, 73 (08)
12345